Reimbursement for genetic variant reinterpretation: five questions payers should ask.
David L Veenstra, John W Rowe, Jos�� A Pag��n, H Shelton Brown, John E Schneider, Avni Gupta, Sara M Berger, Wendy K Chung, Paul S Appelbaum
Author Information
David L Veenstra: Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Box 357630, H375 Health Science Bldg, Seattle, WA 98195-7630. Email: veenstra@uw.edu.
Reaching the goals set by the Health Care Payment and Learning Action Network requires an unyielding and unrelenting focus on encouraging providers to adopt advanced alternative payment models (APMs). Many of these models will continue to be voluntary because they either are in early stages or have not yet proven their effectiveness. The models that have proven their effectiveness should become permanent, comprising the new way that providers are paid in the Medicare program. Either way, getting today's high performers into those programs and keeping them engaged to continue to innovate and set new benchmarks is as important as attracting and improving the performance of poorer performers. That will require a shift in Medicare's policy on pricing and evaluating APMs.
References
BMC Med Genomics. 2019 Nov 29;12(1):170
[PMID: 31779608]
